Dr. (prof.) Anil Mandhani

Dr. (Prof.) Anil Mandhani

Uro-oncologist & Robotic & Minimally Invasive Surgeon
  • MBBS, MS (Surgery), M.Ch. (Urology), DNB (Urology)
  • Fellowship in Robotic Surgery in the Institute of Robotic Surgery Brady Urology Center, NYP
  • Weill Medical College of Cornell University New York, NY. USA
  • Executive Director, Urology and Kidney Transplant
  • Associate Editor, Indian Journal of Urology
Education and Fellowships
2006-07 – Clinical Fellowship in Robotic uro-oncology, Cornell/New York Presbyterian hospital, NY.
1998 – Diplomat of National Board (DNB) in Urology, National Board Examination, India. (Subspecialty Board)
1998 – Magister of Chirugia (M.Ch.) in Urology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India. (Fellowship equivalent)
1993 – Master of Surgery (MS) in General Surgery, Pt. J.N.M. Medical College, Ravi Shankar University, Raipur India. (Surgical Residency)
1990 – Bachelor of Medicine and Bachelor of Surgery (MBBS), Pt. J.N.M. Medical College, Ravi Shankar University, Raipur, India. (MD equivalent)
Professional Affiliations Membership
  • American Urological Association
  • European urological Association
  • British Association of Urological surgeons
  • Indian urological association
  • Editorial Assignment
  • Associate Editor of Indian Journal of Urology
Visiting Faculty
  • Addenbrooke’s Hospital, Cambridge, UK. Dec 2006
  • Mayo Clinic, Rochester, USA June’ 2001
  • Henry Ford health system, Detroit, USA May’04
Awards & Honors
  • Awarded with best reviewer by Journal of Urology in 2017.
  • DUSUCON North zone urological society of India for best research work award. 2014.
  • DUSUCON award on best clinical work on PSA characteristic in prostate cancer. 2013.
  • Awarded Fellow of American College of Surgeon, FACS in 2012.
  • International Guest Scholarship by American College of Surgeons in 2010.
  • Clinical fellowship in Robotic Uro-oncology in New York Presbyterian hospital, NY, USA in 2006-2007. Assisted and done more than 350 robotic radical prostatectomy in one year during this fellowship.
  • “Innovation award” by Urological Society of India for “Endopyelotomy sheath: a new device to facilitate ante grade Endopyelotomy”.
  • Best paper award on ‘prediction of Fragility of stone by DEXA’ in national conference of Urology 2003
  • Har Gobind Singh traveling fellowship of North Zone of Urology India, 2003
  • UICC International Cancer Technology Transfer (ICRETT) fellowship 2004
  • Enrollment in The Marquis who’s who publications board 2002
Work on technology and Research development:
  • Developing a low cost Endocatch.
  • Developing a modified Urostomy bag.
  • Developing Intravesical tumor retrieval device.
  • Developing a new ureterostomy bag (under process for Patent)
Research and Publications
  • Over 200 publications in peer reviewed national and international journals.
  • Grant from Bill and Milinda Gates foundation and DBT for exploratory study with IISC, on “ novel polymeric biomaterial for substitution of urinary bladder and ureter” Phase I study. (GCE-India/R4/2018/003)
  • BIRAC Grant on the development of a new collection device for urine called Urowear.
  • Applied for Patent for the new collecting device for urine.
  • Developing a modified Urostomy bag as startup project with AMTZ Vishakhapatnam.
  • Developing a bio-compatible degradable double J stent with Institute of Science Bangalore.
  • Working on a new device called Foley stent
  • Sureka SK, Yadav A, Arora S, Kapoor R, Mandhani A. Is frozen section analysis of the urethra at the time of radical cystectomy and orthotopic neobladder urinary diversion mandatory? Indian J Urol. 2015 Oct-Dec; 31(4):349-353.
  • Mandhani A, Patina N, Aga P, Pande S, Tewari P. A new classification of inferior vena cava thrombus in renal cell carcinoma could define the need for cardiopulmonary or venovenous bypass. Indian J Urol. 2015 Oct-Dec;31(4):327-332.
  • Agnihotri S, Mittal RD, Kapoor R, Mandhani A. Asymptomatic prostatic inflammation in men with clinical BPH and erectile dysfunction affects the positive predictive value of prostate-specific antigen. Urol Oncol. 2014 Oct; 32(7):946-51.
  • Agnihotri S, Mittal RD, Kapoor R, Mandhani A. Raising cut-off value of prostate specific antigen (PSA) for biopsy in symptomatic men in India to reduce unnecessary biopsy. Indian J Med Res. 2014 Jun; 139(6):851-6.
  • Agnihotri S, Mittal RD, Ahmad S, Mandhani A. Free to total serum prostate specific antigen ratio in symptomatic men does not help in differentiating benign from malignant disease of the prostate. Indian J Urol. 2014 Jan; 30(1):28-32.
  • Sureka SK, Agarwal V, Agnihotri S, Kapoor R, Srivastava A, Mandhani A. Is en-bloc transurethral resection of bladder tumor for non-muscle invasive bladder carcinoma better than conventional technique in terms of recurrence and progression? A prospective study. Indian J Urol. 2014 Apr; 30(2):144-9.